The biopharma industry is getting another chance to get around the inter partes review (IPR) process. So far, companies have struck out trying to alter the process through legislation. And Allergan PLC's controversial maneuver to avoid the proceeding by transferring patent rights to a Native American tribe seems likely to fail. Now, patent owners are anxiously looking to the US Supreme Court to see if it will eliminate inter partes review and require patent disputes to be decided solely in courts.
The high court will hear oral arguments in Oil States Energy Services LLC v. Greene's Energy Group LLC on Nov....
